1. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial 
Ganesh Raghu, MD, Carlos A Pellegrini, MD, Eric Yow, MS, Kevin R Flaherty, MD, Keith Meyer, MD, Imre Noth, MD, Mary Beth Scholand, MD, John Cello, MD, Lawrence A Ho, MD, Sudhakar Pipavath, MD, Joyce S Lee, MD, Jules Lin, MD, James Maloney, MD, Fernando J Martinez, MD, Ellen Morrow, MD, Marco G Patti, MD, Stan Rogers, MD, Paul J Wolters, MD, Robert Yates, MD, Kevin J Anstrom, PhD, Harold R Collard, MD 
The Lancet Respiratory Medicine 
Volume 6, Issue 9, Pages (September 2018)
DOI: /S (18)
Copyright © 2018 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet Respiratory Medicine 2018 6, DOI: ( /S (18) )
Copyright © 2018 Elsevier Ltd Terms and Conditions

3. Figure 2 Change in forced vital capacity and deaths by treatment group
(A) The mean change in forced vital capacity from randomisation to week 48. Error bars are standard error. (B) The disease course of the five patients who died during the study. Percentages are measured forced vital capacity in percentage of predicted and acute exacerbations. Each bar ends at the time of the patient's death. MLC=metastatic lung cancer. MI=myocardial infarction. AEx-D=definite acute exacerbations. AEx-S=suspected acute exacerbations.
The Lancet Respiratory Medicine 2018 6, DOI: ( /S (18) )
Copyright © 2018 Elsevier Ltd Terms and Conditions

4. Figure 3 Kaplan-Meier estimates
(A) Time to the composite endpoint of 10% decline in forced vital capacity or death. (B) Time to the composite endpoint of respiratory hospitalisation or death.
The Lancet Respiratory Medicine 2018 6, DOI: ( /S (18) )
Copyright © 2018 Elsevier Ltd Terms and Conditions